Goldman Sachs Group Inc. raised its position in shares of Ra Pharmctl Inc (NASDAQ:RARX) by 7.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 73,103 shares of the company’s stock after purchasing an additional 4,751 shares during the period. Goldman Sachs Group Inc. owned 0.32% of Ra Pharmctl worth $1,370,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Tekla Capital Management LLC purchased a new stake in shares of Ra Pharmctl during the 2nd quarter worth about $7,418,000. Numeric Investors LLC purchased a new stake in shares of Ra Pharmctl during the 2nd quarter worth about $2,484,000. OxFORD Asset Management LLP purchased a new stake in shares of Ra Pharmctl during the 2nd quarter worth about $1,262,000. VHCP Management II LLC raised its stake in shares of Ra Pharmctl by 6.2% during the 2nd quarter. VHCP Management II LLC now owns 769,771 shares of the company’s stock worth $14,426,000 after purchasing an additional 44,742 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Ra Pharmctl by 28.3% during the 2nd quarter. Vanguard Group Inc. now owns 346,602 shares of the company’s stock worth $6,496,000 after purchasing an additional 76,349 shares in the last quarter. 66.80% of the stock is owned by institutional investors.

A number of equities research analysts have recently weighed in on RARX shares. Zacks Investment Research downgraded Ra Pharmctl from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. Jefferies Group LLC reaffirmed a “buy” rating and set a $25.00 price target on shares of Ra Pharmctl in a research note on Friday, July 14th. Finally, Royal Bank Of Canada started coverage on Ra Pharmctl in a research note on Thursday, September 14th. They set an “outperform” rating and a $21.00 price target for the company. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Ra Pharmctl currently has an average rating of “Buy” and a consensus target price of $24.00.

Shares of Ra Pharmctl Inc (NASDAQ:RARX) opened at $12.31 on Friday.

Ra Pharmctl (NASDAQ:RARX) last announced its earnings results on Wednesday, August 9th. The company reported ($0.56) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.50) by ($0.06). equities research analysts predict that Ra Pharmctl Inc will post -2.54 EPS for the current fiscal year.

WARNING: “Goldman Sachs Group Inc. Purchases 4,751 Shares of Ra Pharmctl Inc (RARX)” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/goldman-sachs-group-inc-purchases-4751-shares-of-ra-pharmctl-inc-rarx/1677567.html.

About Ra Pharmctl

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Want to see what other hedge funds are holding RARX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ra Pharmctl Inc (NASDAQ:RARX).

Institutional Ownership by Quarter for Ra Pharmctl (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmctl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmctl Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.